{"qas": [{"question": "What drugs are the least expensive to develop?", "id": "571ae71a32177014007e9fc6", "answers": [{"text": "those based on re-formulation of an existing active ingredient", "answer_start": 694}], "is_impossible": false}, {"question": "What accounts for nearly half of the costs to develop drugs?", "id": "571ae71a32177014007e9fc7", "answers": [{"text": "opportunity cost of investing capital", "answer_start": 51}], "is_impossible": false}, {"question": "What is the consequence in the value chain?", "id": "571ae71a32177014007e9fc8", "answers": [{"text": "increasingly outsource risks related to fundamental research", "answer_start": 435}], "is_impossible": false}, {"question": "What happens when companies outsource?", "id": "571ae71a32177014007e9fc9", "answers": [{"text": "somewhat reshapes the industry ecosystem with biotechnology companies", "answer_start": 503}], "is_impossible": false}, {"question": "What is re-formulations of active ingredients referred to?", "id": "571ae71a32177014007e9fca", "answers": [{"text": "Line-extensions", "answer_start": 778}], "is_impossible": false}, {"question": "Investing capital can increase drug development costs by how much?", "id": "571d1d495efbb31900334ea8", "answers": [{"text": "nearly half the total expense", "answer_start": 284}], "is_impossible": false}, {"question": "What kind of companies have had a more important role in drug development?", "id": "571d1d495efbb31900334ea9", "answers": [{"text": "biotechnology", "answer_start": 549}], "is_impossible": false}, {"question": "What firms tend to outsource drug development?", "id": "571d1d495efbb31900334eaa", "answers": [{"text": "major pharmaceutical multinationals", "answer_start": 391}], "is_impossible": false}, {"plausible_answers": [{"text": "those based on re-formulation of an existing active ingredient", "answer_start": 694}], "question": "What drugs are the least fundamental to develop?", "id": "5ad399f2604f3c001a3fe843", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "opportunity cost of investing capital", "answer_start": 51}], "question": "What accounts for nearly half of the costs to develop companies?", "id": "5ad399f2604f3c001a3fe844", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "increasingly outsource risks related to fundamental research", "answer_start": 435}], "question": "What is the consequence in the research chain?", "id": "5ad399f2604f3c001a3fe845", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "somewhat reshapes the industry ecosystem with biotechnology companies", "answer_start": 503}], "question": "What happens when companies approve drugs?", "id": "5ad399f2604f3c001a3fe846", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "Line-extensions", "answer_start": 778}], "question": "What is re-formulations of approved drugs referred to?", "id": "5ad399f2604f3c001a3fe847", "answers": [], "is_impossible": true}], "context": "Some of these estimates also take into account the <a1_0><b9_0>opportunity cost of investing capital<b9_0/><a1_0/> many years before revenues are realized (see Time-value of money). Because of the very long time needed for discovery, development, and approval of pharmaceuticals, these costs can accumulate to <a5_0>nearly half the total expense<a5_0/>. A direct consequence within the pharmaceutical industry value chain is that <a7_0>major pharmaceutical multinationals<a7_0/> tend to <a2_0><b10_0>increasingly outsource risks related to fundamental research<b10_0/><a2_0/>, which <a3_0><b11_0>somewhat reshapes the industry ecosystem with <a6_0>biotechnology<a6_0/> companies<b11_0/><a3_0/> playing an increasingly important role, and overall strategies being redefined accordingly. Some approved drugs, such as <a0_0><b8_0>those based on re-formulation of an existing active ingredient<b8_0/><a0_0/> (also referred to as <a4_0><b12_0>Line-extensions<b12_0/><a4_0/>) are much less expensive to develop."}